Buscar
Mostrando ítems 1-10 de 165
Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset
(Elsevier, 2015)
Research aimed at developing new therapies for Parkinson's disease (PD) critically depend on valid animal models of the disease that allows for repeated testing of motor disabilities over extended time periods. We here ...
A model of pediatric end-stage lung failure in small lambs <20 kg
(Lippincott Williams & Wilkins, 2020)
One in five children with end-stage lung failure (ESLF) die while awaiting lung transplant. No suitable animal model of ESLF exists for the development of artificial lung devices for bridging to transplant. Small lambs ...
Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
(2016)
Fetal or intrauterine growth restriction (FGR or IUGR) is a concerning health issue not only due to its implications in mortality and morbidity of neonates but also because of its long-term consequences on health and disease ...
Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson’s disease
(Taylor and Francis Ltd, 2017)
Copyright © 2016 Informa UK Limited, trading as Taylor & Francis Group.Neuromodulation by spinal cord stimulation has been proposed as a symptomatic treatment for Parkinson’s disease. We tested the chronic effects of spinal ...
Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe2+/Cu2+ Chelator in Cell and Animal Models of Parkinson’s Disease
(American Chemical Society, 2017)
© 2016 American Chemical Society.Disturbed iron homeostasis, often coupled to mitochondrial dysfunction, plays an important role in the progression of common neurodegenerative diseases such as Parkinson’s disease (PD). ...
Assessment of in vivo fetal growth and placental vascular function in a novel intrauterine growth restriction model of progressive uterine artery occlusion in guinea pigs
(WILEY-BLACKWEL, 2016)
Intra-uterine growth restriction (IUGR) is associated with short and long-term metabolic and cardiovascular alterations. Mice and rats have been extensively used to study the effects of IUGR, but there are notable differences ...
Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson’s disease
(Springer, 2016)
L-Dopa continues to be the gold drug in Parkinson's disease ( PD) treatment from 1967. The failure to translate successful results from preclinical to clinical studies can be explained by the use of preclinical models which ...
Gene therapy to target ER stress in brain diseases
(Elsevier B.V., 2016)
© 2016 Elsevier B.V. Gene therapy based on the use of Adeno-associated viruses (AAVs) is emerging as a safe and stable strategy to target molecular pathways involved in a variety of brain diseases. Endoplasmic reticulum ...
AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease
(2012)
Huntington's disease (HD) is caused by mutations that expand a polyglutamine region in the amino-terminal domain of Huntingtin (Htt), leading to the accumulation of intracellular inclusions and progressive neurodegeneration. ...